Creating vaccines to fight a virus linked to certain cancers
Official title: Development of three KSHV vaccine platforms and chimeric MHV68-K-G for in vivo mouse infection study
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11002590 · Data updated 2026-11-12
This study is testing new vaccines to help protect against a virus linked to serious health issues like Kaposi's sarcoma, using mice to see how well these vaccines work.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 19, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $989,903 |
| NIH project number | 1U01CA294881-01 |
| Project ID | NIH-11002590 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for KSHV-related diseases, including those with compromised immune systems or those living in endemic regions.
✕Less likely to help
Patients who are not at risk for KSHV infection or those who do not have related health conditions may not benefit from this research.
What this research studies
This research focuses on developing three innovative vaccine platforms aimed at combating Kaposi's sarcoma-associated herpesvirus (KSHV), which is linked to serious conditions like Kaposi's sarcoma and primary effusion lymphomas. The researchers will utilize a mouse model to test these vaccines, employing a modified version of another virus, Murine Herpesvirus 68, to simulate KSHV infection. By doing so, they hope to evaluate the effectiveness of these vaccines in preventing KSHV-related diseases.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that prevent KSHV infection and its associated cancers, significantly improving patient outcomes.
How similar studies have gone: While vaccine development for KSHV is relatively novel, similar approaches using animal models have shown promise in other viral vaccine research.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Jung, Jae U — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Jung, Jae U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.